Table 2.

Characteristics of women who underwent liver transplantation in the United States 2008–2017, by length of stay ^†

		Length of stay <20 days (n = 7,246)	Length of stay ≥20 days (n = 2,454)	p-value
Demographics, comorbidities, and liver disease history
Age at listing, years		55 (48–61)	56 (49–62)	<0.001
Ethnicity	White	71.2	68.5	<0.001
	Black	11.6	9.8
	Hispanic	12.9	17.8
	Asian	2.4	2.6
	Other	1.9	1.4
Liver diagnosis	Alcohol	15.8	17.2	0.05
	Hepatitis C	23.2	22.7
	NASH/Cryptogenic	19.2	20.7
	Hepatitis B	9.0	8.8
	Autoimmune/cholestatic	23.7	21.2
	Other	7.9	8.6
History of prior transplant		2.3	2.9	1.1
Height, cm		163 (158–168)	163 (158–168)	<0.001
Obesity		41.8	43.0	0.31
Diabetes		24.4	26.8	0.02
Insurance	Private	53.5	48.0	<0.001
	Medicaid	16.5	20.1
	Medicare	27.6	29.7
Region risk	Low	53.6	35.4	0.003
	Medium	14.9	17.9
	High	31.5	46.7
Clinical characteristics at time of transplant
Age, years		55 (48–61)	57 (50–63)	<0.001
MELDNa		27 (22–34)	33 (27–39)	<0.001
Hepatic encephalopathy		71.8	78.5	<0.001
Ascites		85.6	87.8	0.008
Portal vein thrombus		10.9	12.3	0.07
Dialysis		16.5	38.7	<0.001
Life support		10.6	8.4	<0.001
Karnofsky Performance Status		50 (30–70)	30 (20–50)	<0.001
KPS Category	Unable to care for self	46.0	73.1	<0.001
	Unable to work	42.0	22.4
	Normal activity	12.0	4.5
Donor risk index		1.5 (1.2–1.8)	1.5 (1.2–1.8)	0.05
Health resource utilization pre-transplant
Hospitalized pre-transplant		36.3	66.7	<0.001
Prolonged hospitalization (> 10d) pre-transplant		17.2	44.5	<0.001
Transplanted from ICU		11.9	36.1	<0.001

^†Data presented as percent or median (interquartile range)

Nonalcoholic steatohepatitis (NASH); Model for End-Stage Liver Disease with Sodium (MELDNa); Karnofsky Performance Score (KPS); intensive care unit (ICU).